Fintel reports that on November 5, 2024, Stifel upgraded their outlook for Alkermes (NasdaqGS:ALKS) from Hold to Buy. Analyst ...

Stifel has upgraded Alkermes (ALKS) to buy from hold, citing increased confidence in the company’s narcolepsy drug candidate ALKS2680. Read more here.

Stifel analyst Paul Matteis upgraded Alkermes (ALKS) to Buy from Hold with a price target of $36, up from $25. Published first on TheFly ...

Stifel upgraded Alkermes (ALKS) to Buy from Hold with a price target of $36, up from $25. After a deep dive on the orexin space, the firm says ...

Check the time stamp on this data. Updated AI-Generated Signals for Alkermes Plc (ALKS) available here: ALKS.

Global Alcoholic Hepatitis Treatment MarketAccording to a recent analysis by Future Market Insights (FMI), the global ...

Alkermes (NASDAQ:ALKS – Get Free Report) had its target price dropped by equities researchers at The Goldman Sachs Group from ...

Alkermes (NASDAQ:ALKS – Get Free Report)‘s stock had its “overweight” rating reiterated by equities researchers at Piper ...

Alkermes plc ALKS reported adjusted earnings from continuing operations of 73 cents per share for third-quarter 2024, which ...

The biopharma company's third-quarter report highlighted robust proprietary product performance, despite some weakness ...

Alkermes (ALKS) reported $378.14 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 0.7%. EPS of $0.73 for the same period compares to $0.64 a year ago.

The opioid addiction treatment market will be worth $2.4bn by 2033, driven by diagnoses in the eight major world markets.